Shancigusin I exhibits significant anti-inflammatory and immunomodulatory activities, making it a candidate for development in treating chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. It has been shown to inhibit key signaling pathways like NF-κB, reducing the production of pro-inflammatory cytokines. Additionally, Shancigusin I demonstrates neuroprotective potential in preclinical models, suggesting possible application in neurodegenerative conditions such as Alzheimer’s disease. Its ability to cross the blood-brain barrier enhances its suitability for central nervous system-targeted therapies. Research also indicates antitumor properties through induction of apoptosis and suppression of tumor cell proliferation, particularly in liver and breast cancer cell lines. These multifaceted biological activities position Shancigusin I as a promising lead compound for drug development in oncology, neurology, and immunology.